Discovery of 2-(Phenoxypyridine)-3-phenylureas as Small Molecule P2Y1 Antagonists

被引：46

作者：

Chao, Hannguang ^{[1
]}

Turdi, Huji ^{[1
]}

Herpin, Timothy F. ^{[1
]}

Roberge, Jacques Y. ^{[1
]}

Liu, Yalei ^{[1
]}

Schnur, Dora M. ^{[1
]}

Poss, Michael A. ^{[1
]}

Rehfuss, Robert ^{[1
]}

Hua, Ji ^{[1
]}

Wu, Qimin ^{[1
]}

Price, Laura A. ^{[1
]}

Abell, Lynn M. ^{[1
]}

Schumacher, William A. ^{[1
]}

Bostwick, Jeffrey S. ^{[1
]}

Steinbacher, Thomas E. ^{[1
]}

Stewart, Anne B. ^{[1
]}

Ogletree, Martin L. ^{[1
]}

Huang, Christine S. ^{[1
]}

Chang, Ming ^{[1
]}

Cacace, Angela M. ^{[1
]}

Arcuri, Maredith J. ^{[1
]}

Celani, Deborah ^{[1
]}

Wexler, Ruth R. ^{[1
]}

Lawrence, R. Michael ^{[1
]}

机构：

[1] Bristol Myers Squibb Res & Dev, Princeton, NJ 08543 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2013年 / 56卷 / 04期

关键词：

NUCLEOTIDE RECEPTORS; DERIVATIVES; CLOPIDOGREL; ANALOGS; PRASUGREL; ASPIRIN; AZD6140; POTENT;

D O I：

10.1021/jm301708u

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Two distinct G protein-coupled purinergic receptors, P2Y(1) and P2Y(12), mediate ADP-driven platelet activation. The clinical effectiveness of P2Y(12) blockade is well established Recent preclinical data suggest that P2Y(1) and P2Y(12) inhibition provide equivalent antithrombotic efficacy, while targeting P2Y(1) has the potential for reduced bleeding liability. In this account, the discovery of a 2-(phenoxypyridine)-3-phenylurea chemotype that inhibited ADP mediated platelet aggregation in human blood samples is described Optimization of this series led to the identification of compound 16, 1-(2-(2-tert-butylphenoxy)pyridin-3-yl)-3-4-(trifluoromethoxy)phenylurea, which demonstrated a 68 +/- 7% thrombus weight reduction in an established rat arterial thrombosis model (10 mg/kg plus 10 mg/kg/h) while only prolonging cuticle and mesenteric bleeding times by 3.3- and 3.1-fold, respectively, in provoked rat bleeding time models. These results suggest that a P2Y(1) antagonist could potentially provide a safe and efficacious antithrombotic profile.

引用

页码：1704 / 1714

页数：11

共 37 条

[1] International union of pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy
Abbracchio, Maria P.
Burnstock, Geoffrey
Boeynaems, Jean-Marie
Barnard, Eric A.
Boyer, Jose L.
Kennedy, Charles
Knight, Gillian E.
Fumagalli, Marta
Gachet, Christian
Jacobson, Kenneth A.
Weisman, Gary A.
[J]. PHARMACOLOGICAL REVIEWS, 2006, 58 (03) : 281 - 341
[2] PURINOCEPTORS - ARE THERE FAMILIES OF P2X AND P2Y PURINOCEPTORS
ABBRACCHIO, MP
BURNSTOCK, G
[J]. PHARMACOLOGY & THERAPEUTICS, 1994, 64 (03) : 445 - 475
[3] Overview of P2Y receptors as therapeutic targets
Boeynaems, JM
Robaye, B
Janssens, R
Suarez-Huerta, N
Communi, D
[J]. DRUG DEVELOPMENT RESEARCH, 2001, 52 (1-2) : 187 - 189
[4] Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2′-deoxyadenosine 3′,5′-bisphosphate
Boyer, JL
Mohanram, A
Camaioni, E
Jacobson, KA
Harden, TK
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (01) : 1 - 3
[5] Burnstock G, 2000, J PHARMACOL EXP THER, V295, P862
[6] Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors
Camaioni, E
Boyer, JL
Mohanram, A
Harden, TK
Jacobson, KA
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (02) : 183 - 190
[7] New P2Y12 Inhibitors
Cattaneo, Marco
[J]. CIRCULATION, 2010, 121 (01) : 171 - 179
[8] CHAO HJ, 2005, Patent No. 20051133511
[9] Costanzi S., 2010, BIOORG MED CHEM LETT, V20, P5254
[10] P2Y receptor subtypes evoke different Ca2+ signals in cultured aortic smooth muscle cells
Govindan, Sriram
Taylor, Colin W.
[J]. PURINERGIC SIGNALLING, 2012, 8 (04) : 763 - 777

← 1 2 3 4 →